Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta Group has the GF Score of 93, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Medacta Group
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Medacta Group (OTCPK:MEDGF) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Medacta Group GF Score Related Terms
MEDGF vs ABT, SYK, MDT: GF Score Comparison
For the Medical Devices subindustry, Medacta Group's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's GF Score distribution charts can be found below:
* The bar in red indicates where Medacta Group's GF Score falls into.
Medacta Group (MEDGF) has a GF Score of 93 as of Jul. 17, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Medacta Group and its competitors. This is near median its historical median of 89.00. Over the past decade, Medacta Group's GF Score has ranged from 16.00 to 98.00.
Is Medacta Group's GF Score too high?
Medacta Group's current GF Score of 93 is near median its 10-year median of 89.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 98.00. Overall, Medacta Group has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's GF Score compare to ABT and SYK?
Medacta Group's GF Score of 93 can be compared against companies in the Medical Devices & Instruments industry. Historically, Medacta Group's own GF Score has ranged from 16.00 to 98.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Medacta Group and its competitors. Medacta Group's current GF Score is 93, which is near median its own 10-year median of 89.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Medacta Group (MEDGF) has a current GF Score of 93. The stock's GF Value™ is $100.71, compared to a current price of $83.91 — trading 16.7% below its estimated fair value. The current GF Score is 93, which is near median its 10-year median of 89.00. Medacta Group's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Medacta Group (MEDGF), the current GF Score is 93 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (MEDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of $83.91 is trading 16.7% below its estimated GF Value™ of $100.71.
Key valuation signals for MEDGF:
GF Score: 93 (near median its 10-year median of 89.00)
GF Value™: $100.71 vs. price of $83.91 (16.7% below fair value)
No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
93GF Score
Get the complete analysis for MEDGF
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDGF has been successfully added to your 
